Erythromycin Eye Ointment for Coliform Infections
Erythromycin eye ointment is not recommended as first-line therapy for coliform (gram-negative) ocular infections as fluoroquinolones are more effective against these pathogens. 1
Recommended Treatment Approach for Coliform Eye Infections
First-line Treatment Options
- Topical fluoroquinolones are recommended as first-line therapy for bacterial keratitis caused by gram-negative organisms like coliforms due to their broad-spectrum coverage 1
- Fourth-generation fluoroquinolones (moxifloxacin, gatifloxacin) provide excellent coverage against gram-negative pathogens while offering improved gram-positive coverage compared to earlier generations 1
- Fluoroquinolones have been shown to be as effective as combination fortified antibiotic therapy for bacterial keratitis in multiple clinical trials 1, 2
Alternative Treatment Options
- For severe infections or cases unresponsive to initial therapy, combination fortified-antibiotic therapy should be considered 1
- Aminoglycosides (gentamicin, tobramycin) provide good coverage against gram-negative bacteria including coliforms and may be used in combination with other agents 1, 3
- For multidrug-resistant Pseudomonas (a gram-negative organism), topical colistin 0.19% may be considered 1
Treatment Administration
- For severe or central corneal infections, aggressive dosing is required - loading doses every 5-15 minutes followed by hourly applications 2
- Frequency of reevaluation depends on severity - severe cases should be followed daily initially until clinical improvement is confirmed 1
- For lesions close to the limbus, consider additional use of systemic antibiotics 1
Efficacy Considerations
- A Cochrane review found no evidence of difference in corneal perforation rates between different classes of topical antibiotics 1
- Fluoroquinolones are associated with reduced eye discomfort compared to aminoglycoside-cephalosporin combinations 1
- Single-drug therapy using fluoroquinolones has been shown to be as effective as combination therapy utilizing fortified antibiotics 2
Important Caveats
- Resistance patterns should be considered - there has been increasing resistance to fluoroquinolones in some regions (e.g., P. aeruginosa resistance to moxifloxacin increased from 19% to 52% in southern India) 1
- Erythromycin, while effective for some gram-positive infections and commonly used in neonatal prophylaxis, has limited activity against gram-negative organisms like coliforms 4, 3
- Fortified antibiotics should be prepared by a compounding pharmacy that is a member of the Pharmacy Compounding Accreditation Board and designated by the FDA as a 503A and/or 503B facility 1
- Risk factors for fluoroquinolone resistance include recent fluoroquinolone use, hospitalization, advanced age, and recent ocular surgery 2
Monitoring and Follow-up
- Severe cases (deep stromal involvement or infiltrates larger than 2 mm with extensive suppuration) require daily follow-up initially 1
- Consider culture and sensitivity testing if the infection does not respond to initial therapy 5
- Topical corticosteroid therapy may be considered after initial control of infection to reduce inflammation and subsequent corneal scarring 1